Last update 01 Nov 2024

Roche Registration GmbH

Subsidiary Company|
Germany

Overview

Tags

Other Diseases
Neoplasms
Skin and Musculoskeletal Diseases
Small molecule drug
Monoclonal antibody
Colony-stimulating factors

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms22
Hemic and Lymphatic Diseases17
Immune System Diseases17
Nervous System Diseases16
Endocrinology and Metabolic Disease13
Infectious Diseases11
Top 5 Drug TypeCount
Monoclonal antibody12
Small molecule drug12
Colony-stimulating factors2
Antibody drug conjugate (ADC)2
Bispecific T-cell Engager (BiTE)2
Top 5 TargetCount
CD20(B-lymphocyte antigen CD20)3
HER2(Receptor tyrosine-protein kinase erbB-2)2
CD20 x CD32
EPO receptor(Erythropoietin receptor)2
CEN(cap-dependent endonuclease)1

Related

34
Drugs associated with Roche Registration GmbH
Crovalimab
Target
C5
Mechanism
C5 inhibitors
Active Org.
Hoffmann-La Roche, Inc. [+7]
Originator Org.
Chugai Pharmaceutical Co., Ltd.Chugai Pharmaceutical Co., Ltd.
Active Indication
Hemoglobinuria, Paroxysmal [+3]
Inactive Indication
Guillain-Barre Syndrome [+1]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
CN
First Approval Date06 Feb 2024
Glofitamab
Target
CD20 x CD3
Mechanism
CD20 inhibitors [+2]
Active Org.
Roche Holding AGRoche Holding AG [+9]
Originator Org.
F. Hoffmann-La Roche Ltd.
Active Indication
Diffuse large B-cell lymphoma recurrent [+22]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
CA
First Approval Date24 Mar 2023
Mosunetuzumab
Target
CD20 x CD3
Mechanism
CD20 inhibitors [+1]
Active Org.
Genentech, Inc.Genentech, Inc. [+6]
Originator Org.
Genentech, Inc.Genentech, Inc.
Active Indication
Follicular Lymphoma [+17]
Inactive Indication
B-cell lymphoma refractory [+2]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
EU [+3]
First Approval Date03 Jun 2022
1
Clinical Trials associated with Roche Registration GmbH
CTR20213006 / RecruitingPhase 3
一项在PD-L1高表达、未接受过化疗的IV期非鳞状或鳞状非小细胞肺癌患者中评估阿替利珠单抗（抗PD-L1抗体）疗效及安全性的III期单臂多中心研究
[Translation] A phase III, single-arm, multicenter study evaluating the efficacy and safety of atezolizumab (anti-PD-L1 antibody) in patients with stage IV non-squamous or squamous non-small cell lung cancer who have high PD-L1 expression and have not received chemotherapy
100 Clinical Results associated with Roche Registration GmbH
Login to view more data
0 Patents (Medical) associated with Roche Registration GmbH
Login to view more data
100 Deals associated with Roche Registration GmbH
Login to view more data
100 Translational Medicine associated with Roche Registration GmbH
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
32
2
Other
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free